Natera (NASDAQ:NTRA) Given New $165.00 Price Target at Canaccord Genuity Group

Natera (NASDAQ:NTRA) had its target price lifted by equities research analysts at Canaccord Genuity Group from $150.00 to $165.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s price target indicates a potential upside of 22.11% from the stock’s previous close.

Other analysts have also recently issued reports about the company. UBS Group dropped their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. The Goldman Sachs Group raised their target price on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen raised their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Sanford C. Bernstein raised their target price on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.13.

Natera Stock Up 0.9 %

Shares of Natera stock opened at $135.12 on Wednesday. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The business’s 50 day simple moving average is $125.09 and its 200-day simple moving average is $114.52. The stock has a market capitalization of $16.71 billion, a price-to-earnings ratio of -55.15 and a beta of 1.53. Natera has a twelve month low of $46.96 and a twelve month high of $140.00.

Insider Transactions at Natera

In other news, insider Jonathan Sheena sold 12,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the sale, the insider now directly owns 287,441 shares of the company’s stock, valued at $34,783,235.41. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, insider Solomon Moshkevich sold 256 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the sale, the insider now directly owns 111,891 shares of the company’s stock, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Sheena sold 12,000 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00. Following the sale, the insider now directly owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,464 shares of company stock valued at $5,849,977 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. boosted its position in shares of Natera by 19.2% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 9,047 shares of the medical research company’s stock worth $827,000 after buying an additional 1,457 shares during the period. Swiss National Bank boosted its position in shares of Natera by 1.5% in the first quarter. Swiss National Bank now owns 225,400 shares of the medical research company’s stock worth $20,615,000 after buying an additional 3,300 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after buying an additional 9,781 shares during the period. Bleakley Financial Group LLC acquired a new stake in shares of Natera in the first quarter worth $223,000. Finally, Entropy Technologies LP acquired a new stake in shares of Natera in the first quarter worth $788,000. 99.90% of the stock is owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.